Mavyret Must Be Taken Once Daily, Not BID or TID
Mavyret (glecaprevir/pibrentasvir) is dosed as 3 tablets taken together once daily with food—it cannot be split into twice-daily (BID) or three-times-daily (TID) dosing. This is the FDA-approved and guideline-recommended regimen that has been studied and proven effective 1.
Why Once-Daily Dosing Is Required
The pharmacokinetic profile of Mavyret was specifically designed and tested for once-daily administration:
- Glecaprevir has a half-life of approximately 6 hours 2
- Pibrentasvir has a half-life of approximately 23 hours 2
- The combination achieves therapeutic drug levels when all 3 tablets (300 mg glecaprevir/120 mg pibrentasvir total daily dose) are taken together once daily 1
Food significantly increases glecaprevir absorption by 83-163%, which is why the medication must be taken with food 2. Splitting the dose would alter these carefully calibrated pharmacokinetics and potentially compromise efficacy.
Clinical Trial Evidence
All pivotal trials that established Mavyret's high cure rates (96-100% SVR12) used once-daily dosing 3, 4, 5:
- The EXPEDITION-1 trial achieved 99% SVR12 in cirrhotic patients with once-daily dosing 3
- The ENDURANCE trials demonstrated 95-99% cure rates across genotypes 1-6 with once-daily administration 4
- The EXPEDITION-8 trial showed 97.7% SVR12 in treatment-naïve patients with compensated cirrhosis using once-daily dosing 5
No studies have evaluated or validated BID or TID dosing schedules for Mavyret.
Guideline Recommendations
The 2020 EASL guidelines explicitly state: "The recommended dose is 3 tablets taken orally once daily with food" 2. The 2020 AASLD-IDSA guidelines similarly recommend once-daily dosing for all approved indications 6.
Critical Pitfalls to Avoid
- Do not split the daily dose: There is no evidence supporting divided dosing, and doing so may lead to subtherapeutic drug levels and treatment failure
- Do not confuse with other HCV regimens: Some older interferon-based regimens required multiple daily doses, but modern DAAs like Mavyret are designed for once-daily convenience
- Ensure adherence to food requirement: Taking without food reduces glecaprevir exposure by up to 62%, potentially compromising efficacy 2
Practical Administration
For patients who have difficulty swallowing three tablets at once:
- The tablets can be taken sequentially within the same dosing occasion, but all three must be taken together (not split throughout the day) 1
- For pediatric patients <45 kg, oral pellet formulations are available that are also dosed once daily 1
The once-daily regimen maximizes both efficacy and adherence—there is no clinical rationale or evidence base for altering this to BID or TID dosing.